beta cells
Showing 26 - 50 of >10,000
Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))
Recruiting
- Transfusion Dependent Beta-Thalassemia
- GMCN-508B (LentiRed)
-
Nanning, Guangxi, ChinaThe affiliated hospital of guangxi medical university
Feb 28, 2023
ß Thalassemia Major Trial in Shanghai (?-globin reactivated autologous hematopoietic stem cells)
Active, not recruiting
- β Thalassemia Major
- γ-globin reactivated autologous hematopoietic stem cells
-
Shanghai, Shanghai, ChinaShanghai Bioray Laboratories Inc.
Oct 9, 2022
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))
Not yet recruiting
- Leukemia
- +12 more
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- (no location specified)
Mar 20, 2023
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
Multiple Myeloma Trial in Stanford (MGTA-145, Plerixafor)
Completed
- Multiple Myeloma
-
Stanford, CaliforniaStanford University
Aug 17, 2022
Thalassemia Major Trial in Shanghai (?-globin reactivated autologous hematopoietic stem cells)
Not yet recruiting
- Thalassemia Major
- γ-globin reactivated autologous hematopoietic stem cells
-
Shanghai, Shanghai, ChinaShanghai Bioray Laboratories Inc
Jul 1, 2022
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Cleveland
Not yet recruiting
- Allogeneic Stem Cell Transplant Candidate
- +4 more
- Cellular therapy product
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jul 1, 2022
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,
Recruiting
- Colorectal Cancer
- +11 more
- Vactosertib
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023
Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)
Completed
- Mantle Cell Lymphoma
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)
Recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Basiliximab
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 16, 2022
Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)
Not yet recruiting
- Beta-Thalassemia
- +6 more
- CTX001
- (no location specified)
Jul 26, 2022
Leukemia, Bone Marrow Failure Syndrome, Immunodeficiencies Trial in Philadelphia (Apha/beta T and CD19+ cell depletion using
Available
- Leukemia
- +2 more
- Apha/beta T and CD19+ cell depletion using CliniMACS device
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Nov 2, 2021
Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)
Active, not recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Guangzhou, Guangdong, China
- +3 more
May 9, 2022
COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO
Recruiting
- Generation of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During Pregnancy
- no intervention, observation only
-
Bnei Brak, Merkaz, IsraelMaayanei Hayeshua Medical Center
Apr 26, 2021
Hematologic Diseases Trial in Palo Alto (biological, device, drug)
Recruiting
- Hematologic Diseases
- Allogeneic Stem Cell Transplant
- +2 more
-
Palo Alto, CaliforniaLucile Packard Children's Hospital
Mar 25, 2022
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (drug, biological, other)
Completed
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Cytarabine
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 18, 2021
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)
Active, not recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Stanford, California
- +11 more
Nov 30, 2022
Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,
Recruiting
- Recurrent Neuroblastoma
- +3 more
- Cyclophosphamide
- +2 more
-
Palo Alto, California
- +3 more
Jan 25, 2023
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia Trial in United States (drug, radiation,
Recruiting
- Acute Erythroid Leukemia
- +10 more
- Fludarabine
- +5 more
-
San Francisco, California
- +5 more
Nov 1, 2022
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Cladribine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2022
Hematologic Diseases Trial in Palo Alto (Allogeneic Stem Cell Transplant, CliniMACS TCR a/ß Reagent Kit and CliniMACS CD19)
Recruiting
- Hematologic Diseases
- Allogeneic Stem Cell Transplant
- CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
-
Palo Alto, CaliforniaLucile Packard Children's Hospital
Feb 2, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte
Recruiting
- Castration-Resistant Prostate Carcinoma
- +4 more
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022